CAR-T cells have been validated effective in treating CD19 positive B cell lymphoma. Other lymphomas like Hodgkin's lymphoma and anaplastic large cell lymphoma are CD30 positive. In this study, a newly CD30 targeted CART therapy ICAR30 is designed to specifically kill those CD30 expressing malignancies including Hodgkin's lymphoma and CD30+ anaplastic large cell lymphoma. The subjects will receive several doses of autologous ICAR30 T cells infusion and then the safety, treating effects and lasting period of these cells in vivo will be evaluated.

Inclusion Criteria:

Hodgkin's lymphoma, anaplastic large cell lymphoma and other CD30 positive malignancies, relapsed or refractory:

• Karnofsky or Lansky score >50;
• Expected survival>12 weeks;
• Hgb > 8.0;
• FEV1, FVC and DLCO ≥50% of expected corrected for hemoglobin;
• LVEF≥50%;
• Creatinine<2.5mg/dl;
• Bilirubin<2.5mg/dl;
• ALT (alanine aminotransferase)/AST (aspartate aminotransferase)<3 fold normal;
• Patients must sign an informed consent.

Exclusion Criteria:

• Pregnant or lactating;
• Uncontrolled active infection including hepatitis B or C;
• HIV positive;
• Active clinically significant CNS dysfunction;
• Current use of systemic steroids;
• Heterogenous lymphocyte treatments within recent 6 months;

None (Open Label)